- Home
- MCR vs GALT Comparison
MCR vs GALT Comparison
Compare MCR & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCR
- GALT
- Stock Information
- Founded
- MCR 1989
- GALT 2000
- Country
- MCR United States
- GALT United States
- Employees
- MCR N/A
- GALT N/A
- Industry
- MCR Trusts Except Educational Religious and Charitable
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- MCR Finance
- GALT Health Care
- Exchange
- MCR Nasdaq
- GALT Nasdaq
- Market Cap
- MCR 265.5M
- GALT 232.3M
- IPO Year
- MCR N/A
- GALT N/A
- Fundamental
- Price
- MCR $6.42
- GALT $4.75
- Analyst Decision
- MCR
- GALT Strong Buy
- Analyst Count
- MCR 0
- GALT 3
- Target Price
- MCR N/A
- GALT $6.00
- AVG Volume (30 Days)
- MCR 66.7K
- GALT 367.3K
- Earning Date
- MCR 01-01-0001
- GALT 11-12-2025
- Dividend Yield
- MCR 8.52%
- GALT N/A
- EPS Growth
- MCR N/A
- GALT N/A
- EPS
- MCR 0.38
- GALT N/A
- Revenue
- MCR N/A
- GALT N/A
- Revenue This Year
- MCR N/A
- GALT N/A
- Revenue Next Year
- MCR N/A
- GALT N/A
- P/E Ratio
- MCR $16.61
- GALT N/A
- Revenue Growth
- MCR N/A
- GALT N/A
- 52 Week Low
- MCR $5.63
- GALT $0.73
- 52 Week High
- MCR $6.70
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- MCR 50.40
- GALT 60.29
- Support Level
- MCR $6.36
- GALT $4.10
- Resistance Level
- MCR $6.50
- GALT $5.06
- Average True Range (ATR)
- MCR 0.07
- GALT 0.29
- MACD
- MCR -0.01
- GALT -0.05
- Stochastic Oscillator
- MCR 40.11
- GALT 56.25
About MCR MFS Charter Income Trust
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.